Natalie S. Callander, MD,

Articles

Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer Center

May 31st 2023

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Dr Callander on Investigational Maintenance Regimens in Multiple Myeloma

April 6th 2023

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.

Dr Callander on Early CAR T-cell Therapy Referrals in Multiple Myeloma

March 23rd 2023

Natalie S. Callander, MD, discusses the potential benefits of referring patients with multiple myeloma to CAR T-cell therapy earlier in their disease course.

Examining the Importance of the Institutional Perspectives in Cancer Webinars

April 2nd 2021

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Dr. Callander on the Potential Future of Belantamab Mafodotin in Multiple Myeloma

February 19th 2021

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

Dr. Callander on the Expanding Role of Belantamab Mafodotin in Multiple Myeloma

January 28th 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

January 22nd 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Dr. Callander Discusses Combinations in Multiple Myeloma

October 11th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Dr. Callander on Treatment Considerations in Multiple Myeloma

October 10th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.